FEB 22, 2018 06:00 AM PST
Testing for Soluble ST2: Opening New Perspectives for Cardiovascular Diseases
Presented at the Drug Discovery 2018 Virtual Event
1 4 39

  • Professor, Associated Laboratory Director, Saint-Luc University Hospital, Brussels, Belgium
      Professor Damien Gruson was awarded his degree of Pharmacist and later of Specialist in Laboratory Medicine from the Catholic University of Louvain, Brussels, Belgium. He joined the Department of Laboratory Medicine of the St-Luc University Hospital in 2008. He is now associated laboratory director and leading Endocrine Biology. He is also member of the research unit on Endocrinolgy Diabetes and Nutrition of the Catholic University of Louvain. Pr. D. Gruson has published numerous articles in several international peer-reviewed journals. Pr. D. Gruson is a member of the committee on distance learning of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), of the IFCC task force for young scientists (Chair between 2010 and 2012 and now consultant), a member of the division of Endocrinology of the American Association of Clinical Chemistry. Pr. D. Gruson is also a Fellow of the European Society of Cardiology.


    Heart failure (HF) is a major problem for our contemporary societies in terms of prevalence, mortality and cost. Natriuretic peptides are recognized biomarkers for the diagnosis of HF but also for risk stratification. Innovative biomarkers are studied to improve the sub-phenotyping of HF, to facilitate the diagnosis of HF with preserved ejection fraction, and to tailor therapeutic approaches. The soluble receptor of interleukin 33 (sST2) is one of these new biomarkers. In groups of patients at higher risk of HF (hypertension, diabetes), measurement of sST2 could identify patients requiring more sustained management. In the case of HF with reduced ejection fraction, sST2 would be a powerful marker for risk estimation but also to confirm treatment choice. In the case of HF with preserved ejection fraction, measurement of sST2 may be useful for confirming a diagnosis but also for the risk stratification of the patients and as companion marker for the treatment. Interestingly, the determination of the concentrations of sST2 is facilitated by the evolution of assays with new point of care testing methods. As for many innovative biomarkers, the transition of sS2T to routine testing requires strong multidiscilplinary exchanges with physicians.

    Show Resources
    Loading Comments...